Verona Pharma logo

VRP - Verona Pharma Share Price

48.5p 0.0  0.0%

Last Trade - 20/09/19

Sector
Healthcare
Size
Small Cap
Market Cap £51.1m
Enterprise Value £4.72m
Revenue £n/a
Position in Universe 1169th / 1829
Bullish
Bearish
Unlock VRP Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

VRP Revenue Unlock VRP Revenue

Net Income

VRP Net Income Unlock VRP Revenue

Normalised EPS

VRP Normalised EPS Unlock VRP Revenue

PE Ratio Range

VRP PE Ratio Range Unlock VRP Revenue

Dividend Yield Range

VRP Dividend Yield Range Unlock VRP Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2019
31st Dec 2020
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
VRP EPS Forecasts Unlock VRP Revenue
Profile Summary

Verona Pharma plc is a United Kingdom-based clinical-stage biopharmaceutical company. The principal activity of the Company is the development of drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis. The Company's product candidate, RPL554, is a dual inhibitor of the enzymes phosphodiesterase 3 and 4 (PDE3 and PDE4) that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. The Company is developing RPL554 in a nebulized formulation for the maintenance treatment of COPD patients and for the treatment of cystic fibrosis. It also is developing RPL554 as an add-on therapy to commonly used therapies for the treatment of acute exacerbations of COPD in the hospital setting. In addition to its nebulized formulation of RPL554, the Company is developing RPL554 in both dry powder inhaler (DPI) and metered dose inhaler (MDI) formulations for the maintenance treatment of COPD.

Directors
Last Annual December 31st, 2018
Last Interim June 30th, 2019
Incorporated February 24, 2005
Public Since March 30, 2005
No. of Shareholders: n/a
No. of Employees: 14
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Aim All Share ,
Exchange London Stock Exchange (AIM)
Shares in Issue 105,326,638
Free Float (0.0%)
Eligible for
ISAs
SIPPs
VRP Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for VRP
Upcoming Events for VRP
Similar to VRP
© Stockopedia 2019, Thomson Reuters, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.